COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,673 Articles (22,913 medRxiv, 8,760 bioRxiv)

Most recent first Previous |  Page 1012: Articles 10111-10120  | Next

Kinetics and persistence of the cellular and humoral immune responses to BNT162b2 mRNA vaccine in SARS-CoV-2-naive and -experienced subjects
Desmecht, S., Tashkeev, A., Marechal, N., Peree, H., Tokunaga, Y., Fombellida Lopez, C., Polese, B., Legrand, C., Wery, M., Mni, M., Fouillien, N., Toussaint, F., Gillet, L., Bureau, F., Lutteri, L., Hayette, M.-P., Moutschen, M., Meuris, C., Desmecht, D., Rahmouni, S., Gilles, D.
10.1101/2022.01.17.22269278 — Posted: 2022-01-27
Cohort Profile: The United Kingdom Research study into Ethnicity And COVID-19 outcomes in Healthcare workers (UK-REACH)
Bryant, L., Free, R. C., Woolf, K., Melbourne, C., Guyatt, A. L., John, C., Gupta, A., Grey, L. J., Nellums, L., Martin, C. A., McManus, I. C., Garwood, C., Modhawdia, V., Carr, S., Wain, L. V., Tobin, M. D., Khunti, K., Akubakar, I., Pareek, M., UK-REACH Collaborative Group
10.1101/2022.01.19.22268871 — Posted: 2022-01-27
Association of Increased Fluvoxamine Use with Reports of Benefit for COVID
Kojima, N., Qato, D. M., Klausner, J. D.
10.1101/2022.01.19.22269020 — Posted: 2022-01-27
Germinal center-derived broadly neutralizing antibodies adapt to SARS-CoV-2 antigenic drift
Shitaoka, K., Kawano, Y., Higashiura, A., Mizoguchi, Y., Hashiguchi, T., Nishimichi, N., Huang, S., Ito, A., Yamamoto, A., Ohki, S., Kanda, M., Taniguchi, T., Yokosaki, Y., Okada, S., Sakaguchi, T., Yasuda, T.
10.1101/2022.01.26.477937 — Posted: 2022-01-27
Serum proteomics identifies immune pathways and candidate biomarkers of coronavirus infection in wild vampire bats
Becker, D., Lei, G.-S., Janech, M. G., Brand, A. M., Fenton, B., Simmons, N. B., Neely, B. A.
10.1101/2022.01.26.477790 — Posted: 2022-01-27
Ultraviolet Dosage and Decontamination Efficacy was Widely Variable Across 14 UV Devices after Testing a Dried Enveloped Ribonucleic Acid Virus Surrogate for SARS-CoV-2
Buhr, T. L., Borgers-Klonkowski, E., Gutting, B. W., Hammer, E. E., Hamilton, S. M., Huhman, B. M., Jackson, S. L., Kennihan, N. L., Lilly, S. D., Little, J. D., Luck, B. B., Matuczinski, E. A., Miller, C. T., Sides, R. E., Yates, V. L., Young, A. A.
10.1101/2022.01.27.478063 — Posted: 2022-01-27
The P132H mutation in the main protease of Omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition
Sacco, M. D., Hu, Y., Gongora, M. V., Meilleur, F., Kemp, M. T., Zhang, X., Wang, J., Chen, Y.
10.1101/2022.01.26.477774 — Posted: 2022-01-27
Effect of SARS-CoV-2 spike mutations on its activation by TMPRSS2 and TMPRSS13
Stevaert, A., Van Berwaer, R., Raeymaekers, V., Laporte, M., Naesens, L. M. J.
10.1101/2022.01.26.477969 — Posted: 2022-01-27
Antibodies targeting conserved non-canonical antigens and endemic coronaviruses associate with favorable outcomes in severe COVID-19
Peddireddy, S. P., Rahman, S. A., Cillo, A. R., Vijay, G. M., Somasundaram, A., Workman, C. J., Bain, W., McVerry, B. J., Methe, B., Lee, J. S., Ray, P., Ray, A., Bruno, T. C., Vignali, D. A., Kitsios, G. D., Morris, A., Singh, H., Sarkar, A., Das, J.
10.1101/2022.01.24.477545 — Posted: 2022-01-27
Defining the Substrate Envelope of SARS-CoV-2 Main Protease to Predict and Avoid Drug Resistance
Shaqra, A. M., Zvornicanin, S., Huang, Q. Y., Lockbaum, G. J., Knapp, M., Tandeske, L., Barkan, D. T., Flynn, J., Bolon, D. N., Moquin, S., Dovala, D., Kurt Yilmaz, N., Schiffer, C. A.
10.1101/2022.01.25.477757 — Posted: 2022-01-27

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).